About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
CYTK - Cytokinetics| Previous Close | $21.64 | Open | $21.01 |
| Volume | 1.18M | Market Cap | 1.287B |
| Yield | Last Dividend |
| Cytokinetics Reports Second Quarter 2020... | 08/06/20 |
| Top-line Results from GALACTIC-HF Expected in Q4 2020 Licensing Collaboration, Royalty Monetizations and Financing Provide Additional Capitalto Suppor... | |
| Cytokinetics Incorporated : Corporate Pr... | 07/21/20 |
| 35/94 ??? | July 22, 2020 | |
| Cytokinetics Announces Closing of Public... | 07/21/20 |
| SOUTH SAN FRANCISCO, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced the closing of its previously?... | |
| Cytokinetics readies $150M stock offerin... | 07/15/20 |
| Cytokinetics (NASDAQ:CYTK) initiates a $150M public offering of common stock. Price, volume and terms have yet to be announced. | |
| Cytokinetics inks deal for CK-3773274 wi... | 07/14/20 |
| Cytokinetics (NASDAQ:CYTK) has agreed to a series of transactions with certain companies wholly owned by investment funds managed by RTW Investments, ... | |
| Cytokinetics Announces Licensing Collabo... | 07/14/20 |
| $250 Million in Committed Capital to Cytokinetics;Additional $200 Million in Development and Commercialization Milestone Payments Ji Xing Pharmaceutic... | |
| Cytokinetics Announces Licensing Collabo... | 07/14/20 |
| $250 Million in Committed Capital to Cytokinetics;Additional $200 Million in Development and Commercialization Milestone Payments Ji Xing??? | |
| Cytokinetics Announces Participation in ... | 07/13/20 |
| SOUTH SAN FRANCISCO, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is participating in t... | |
| Cytokinetics to host investor/analyst ev... | 07/01/20 |
| Cytokinetics (NASDAQ:CYTK) will host a virtual Investor and Analyst Day on Wednesday, July 15, from 8:30 am - 11:30 am ET. Panel discussions will addr... | |
| Hedge Funds Have Never Been This Bullish... | 06/16/20 |
| In this article you are going to find out whether hedge funds think Cytokinetics, Inc. (NASDAQ:CYTK) is a good investment right now. We like to check ... | |
| Cytokinetics Reports First Quarter 2020 ... | 05/06/20 |
| Top-line Results for GALACTIC-HF Expected in Q4 2020 Ended Q1 with More Than Two Years of Going Forward Cash Based on 2020 Guidance SOUTH SAN??? | |
| Cytokinetics (CYTK) Expected to Beat Ear... | 04/29/20 |
| Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with th... | |
| Cytokinetics Inc (CYTK) Q4 2019 Earnings... | 03/04/20 |
| CYTK earnings call for the period ending January 31, 2020. | |
| The Daily Biotech Pulse: Epizyme's Tazem... | 02/14/20 |
| The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs F... | |
| Cytokinetics (CYTK) May Report Negative ... | 02/13/20 |
| Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared w... | |
| The Daily Biotech Pulse: Deciphera Cance... | 02/13/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 12) ... | |
| The Daily Biotech Pulse: J&J Intensifies... | 02/12/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 11) ... | |
| Cytokinetics Announces Start of Phase 2 ... | 01/06/20 |
| Cytokinetics announced that REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM) has opened to enrollment. ... | |
| Brokerages Set Cytokinetics, Inc. (NASDA... | 11/12/19 |
| Shares of Cytokinetics, Inc. (NASDAQ:CYTK) have been given an average rating of ???Hold??? by the nine ratings firms that are covering the company, Ma... | |
| The Daily Biotech Pulse: Glaukos To Buy ... | 08/08/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 7) A... | |
| The Daily Biotech Pulse: Novartis Stands... | 08/07/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 6) A... | |
| Analysts Estimate Cytokinetics (CYTK) to... | 07/18/19 |
| Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared w... | |
| Cytokinetics, Incorporated. (CYTK) CEO R... | 05/09/19 |
| No summary available. | |
| Cytokinetics files for $200M mixed shelf | 05/09/19 |
| Cytokinetics (CYTK) has filed a prospectus for a $200M mixed shelf offering. | |
| Cytokinetics Inc (CYTK) Q1 2019 Earnings... | 05/09/19 |
| CYTK earnings call for the period ending March 31, 2019. | |
| Cytokinetics (CYTK) Reports Q1 Loss, Top... | 05/09/19 |
| Cytokinetics (CYTK) delivered earnings and revenue surprises of -14.89% and 36.41%, respectively, for the quarter ended March 2019. Do the numbers hol... | |
| Cytokinetics misses by $0.07, beats on r... | 05/09/19 |
| No summary available. | |
| Cytokinetics Suffers Trial Setback, But ... | 05/07/19 |
| No summary available. | |
| FRED, UBS and MT among premarket losers | 05/06/19 |
| No summary available. | |
| Cytokinetics plunges 19% after Phase 2 t... | 05/06/19 |
| Shares of biotech Cytokinetics Inc. plunged 19% in premarket trade Monday after the company announced that a Phase 2 study of its amyotrophic lateral ... | |
| Buy rating | 07/23/20 |
| HC Wainwright & Co. maintains Buy rating and raises Price Target from $38.00 to $59.00 | |
| Strong Buy rating | 07/23/20 |
| Piper Sandler maintains Overweight rating and raises Price Target from $33.00 to $36.00 | |
| Buy rating | 07/16/20 |
| Needham maintains Buy rating and raises Price Target from $34.00 to $45.00 | |
| Buy rating | 07/14/20 |
| HC Wainwright & Co. maintains Buy rating and raises Price Target from $35.00 to $38.00 | |
| rating | 07/10/20 |
| Raymond James initiates coverage with Strong Buy rating and announces Price Target of $39.00 | |
| Strong Buy rating | 07/07/20 |
| Morgan Stanley maintains Overweight rating and raises Price Target from $29.00 to $35.00 | |
| Strong Buy rating | 05/12/20 |
| Morgan Stanley maintains Overweight rating and raises Price Target from $25.00 to $29.00 | |
| Date | 2020-08-06 (AMC) | Est. (EPS/Rev.) | ($0.57)/ 4.07M |
| Actual (EPS/Rev.) | $-0.68/ $3.59 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Tech Trades | Tech Trades | 84.00 % | Follow |
| Arbitrage Trade Analytics | Royce Wells | 71.00 % | Subscribe |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
